Healthcare policy expert William Sarraille has been selected as Special Counsel for ADAP Advocacy, specifically focusing on issues related to the 340B Drug Pricing Program. In this role, Sarraille will provide strategic guidance on public policy, legislative matters, and potential program reforms aimed at better serving patients.
Sarraille brings extensive healthcare expertise to the position, with a comprehensive background in Medicare and Medicaid reimbursement, pharmaceutical pricing, and healthcare compliance. His appointment signals a commitment to critically examining the current implementation of the 340B program and identifying potential improvements.
ADAP Advocacy CEO Brandon M. Macsata emphasized Sarraille's deep understanding of the program's legislative intent, noting concerns about how the program's growth has potentially diverged from its original patient-focused mission. Specifically, Macsata highlighted questions about large hospitals with substantial endowments continuing to benefit while patients face significant cost-sharing challenges.
Sarraille's expertise spans complex healthcare domains, including clinical research, healthcare privacy, and regulatory compliance. His role will involve advising ADAP Advocacy's 340B Patient Advisory Committee and developing strategies to realign the program with its fundamental patient care objectives.
The appointment underscores growing industry scrutiny of healthcare pricing mechanisms and the ongoing effort to ensure drug pricing programs effectively support underserved patient populations.
